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Background: Best supportive care (BSC) as a control arm in clinical trials is poorly defined. We conducted a review to evaluate
clinical trials’ concordance with published, consensus-based framework for BSC delivery in trials.
Methods: A consensus-based Delphi panel previously identified four key domains of BSC delivery in trials: multidisciplinary care;
supportive care documentation; symptom assessment; and symptom management. We reviewed trials including BSC control arms
from 2002 to 2014 to assess concordance to BSC standards and to selected items from the CONSORT 2010 guidelines.
Results: Of 408 articles retrieved, we retained 18 after applying exclusion criteria. Overall, trials conformed to the CONSORT
guidelines better than the BSC standards (28% vs 16%). One-third of articles offered a detailed description of BSC, 61% reported
regular symptom assessment, and 44% reported using validated symptom assessment measures. One-third reported symptom
assessment at identical intervals in both arms. None documented evidence-based symptom management. No studies reported
educating patients about symptom management or goals of therapy. No studies reported offering access to palliative care
specialists.
Conclusions: Reporting of BSC in trials is incomplete, resulting in uncertain internal and external validity. Such studies risk
systematically over-estimating the net clinical effect of the comparator arms.
Randomized controlled trials (RCTs) for patients with advanced
cancer often use a best supportive care (BSC) control arm, whereby
patients randomized to this control arm receive supportive care
exclusive of anti-neoplastic treatment (Macdonald, 1998; Cullen,
2001; Ahmed et al, 2004; Zafar et al, 2008; Cherny et al, 2009).
However, supportive care interventions provided to patients in
BSC control arms are often poorly described in protocols and
manuscripts (Cullen, 2001; Cherny et al, 2009; Zafar et al, 2012).
A prior systematic review found poor reporting of the components
of the BSC arm and a lack of BSC standardization among trial
participants (Cherny et al, 2009). As a result of this lack of rigor in
defining and standardizing BSC, studies including BSC control
arms may have problems with internal and external validity
(Figure 1). These validity concerns may lead to biased outcomes or
flawed conclusions.
A panel of international experts developed consensus-based
standards for delivering BSC in clinical trials (Zafar et al, 2012).
The authors of this framework described four key domains that
should be included in BSC delivery: (1) multidisciplinary care;
(2) documentation of supportive care; (3) symptom assessment at
least as often as the intervention arm; and (4) guideline-based
symptom management (Zafar et al, 2012). Thus, this framework is
intended to guide standardization of BSC in clinical trials similar to
the way other frameworks improve consistency of RCTs and their
reporting. For example, study interventions are described with
great detail in the protocol; the CONSORT statement outlines
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a consistent approach for documentation and reporting of patient
eligibility criteria, study settings, intervention components, and
generalizability of the trial findings (Schulz et al, 2010).
Although accepted standards for the delivery of BSC in RCTs
exist, the literature has not described how well these standards
reflect contemporary trial design. We conducted a review of the
literature to determine whether the consensus-based framework for
BSC delivery in RCTs reflects the design and documentation of
recently published BSC RCTs.
MATERIALS AND METHODS
We searched the MEDLINE/PubMed database from 2002 to 2014
using the following search strings: ‘cancer’; ‘best supportive care’;
‘randomized’ or ‘random allocation’; and ‘supportive’ or ‘palliative.’
We used the following exclusion criteria: no BSC arm, non-human
trial, not randomized, not English, not advanced cancer, or not
including anti-cancer therapy.
We assessed each article for conformance to the consensus-
based guidelines for BSC delivery by determining the presence or
absence of the guideline criteria in the study publication (Table 1).
Similarly, we evaluated each RCT’s concordance to selected
methodological items derived from the updated CONSORT 2010
guidelines for the reporting of RCTs. We selected relevant items
from the CONSORT 2010 guidelines that most closely resemble
the BSC domains. Two reviewers evaluated each article to
determine how well the consensus-based frameworks were
reflected in the documentation of BSC in each trial. Two additional
reviewers resolved any discrepancies to ensure consensus agree-
ment on each particular guideline.
RESULTS
Search results. Of the 408 articles retrieved for potential review,
we retained 18 after applying exclusion criteria (Figure 2). Most of
the trials involved gastrointestinal (39%; 7 out of 18) and lung
(39%; 7 out of 18) malignancies and most were phase III trials
(78%; 14 out of 18) (Table 2). The majority of trials used overall
survival as their primary endpoint (72%; 13 out of 18) and most
concluded that their intervention showed an advantage over BSC
(56%; 10 out of 18).
Conformance to BSC Delphi standards. Overall, trials con-
formed to 16% of the BSC Delphi standards. Although most of the
studies were multisite trials (94%), none of them reported
standardized BSC across study sites (Table 3). Only one of the
studies reported standardized delivery of BSC for the participants
assigned to this arm (6%). The authors of this study discussed
standardizing supportive care in their methods section under the
intervention subheading (O’Brien et al, 2006).
Two-thirds of the articles did not provide a clear description of
what BSC entailed for the patients on the BSC arm. For example, a
common description of care provided in the BSC arm included
details about the patients receiving structured physical, psycholo-
gical, and social assessments with a clear explanation of symptom
management (Muers et al, 2008). Most of the articles described
symptom assessment at regular intervals (61%), but fewer reported
the assessment of symptoms at identical intervals for both arms
(33%), or used validated symptom assessment tools (44%). None of
the articles described the use of evidence-based symptom manage-
ment and none of the articles mentioned the provision of
education to patients regarding how symptoms would be managed.
Similarly, we found that none of the articles discussed educating
patients about the importance of symptom assessment and
management.
Furthermore, none of the articles reported offering education

















• Intervention clearly defined
• Clear documentation
• Standard experimental interventions
• Incomplete definition
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Figure 1. Poorly designed BSC can produce trial results that are internally and externally invalid.
Table 1. BSC and CONSORT domains assessed
BSC domains
Did the trial enroll patients across more than one site?
If yes, was the delivery of BSC standardized across all sites?
Was the delivery of supportive care within the clinical trial documented in a
standardized manner for all patients on trial?
Does publication resulting from the trial offer a clear description of what best
supportive care entailed?
Were symptoms are assessed at baseline and at regular intervals throughout
trial participation?
Were symptoms assessed with concise, globally-accessible, validated tools?
Was symptom assessment undertaken at identical intervals in both arms?
Was symptom management conducted in concordance with evidence-based
guidelines?
Were patients offered education specific to symptom management and
assessment?
Were patients offered education specific to the goals of anti-cancer therapy?
Were patients offered access to palliative care specialists?
Did patients have access to other support services, including high-quality
nursing, social work, financial counseling, and spiritual counseling?
Were patients educated on the goals of anti-cancer therapy, the importance
of symptom assessment, and the role of symptom management within a
clinical trial?
CONSORT domains
Does the study state eligibility criteria for patients?
Does the study document the settings and locations where the data were
collected?
Are the interventions for each group described with sufficient details to allow
replication, including how and when they were actually administered?
Does the trial provide adequate information for the results to be
generalizable?
Abbreviation: BSC¼best supportive care.
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None of the articles mentioned that palliative care specialists were
accessible to patients while receiving therapy. A minority of trials
reported that patients in their study had access to support services
that included social work, financial counseling, or spiritual
counseling (11%).
Conformance to CONSORT. Overall, trials conformed to the
selected CONSORT 2010 guidelines for trial reporting better than
they did to the BSC standards (28% vs 16%). All of the articles
reported eligibility criteria for patients on study. A minority of
articles documented setting and locations of all trial sites (11%).
None of the articles described interventions for each study arm
with sufficient detail to allow replication. Similarly, none of the
trials provided adequate information for the results to be
generalizable.
DISCUSSION
In our review of the cancer clinical trial literature, we found
inconsistent reporting of supportive care provided to trial
participants. In contrast to efforts to standardize intervention
arms, our findings are consistent with prior studies (Ahmed et al,
2004; Cherny et al, 2009) demonstrating that RCTs poorly define
and standardize BSC as a clinical trial control arm. A systematic
review published in 2004 sought to examine the outcomes of RCTs
that compared BSC vs chemotherapy in gastrointestinal cancer
clinical trials (Ahmed et al, 2004). This review concluded that trial
design and reporting needed improvements, and it highlighted
the need for more clearly defined BSC as an RCT control
arm (Ahmed et al, 2004). Similarly, a 2009 systematic review
of the BSC literature called for improvements to the methodolo-
gical and ethical validity of BSC studies (Cherny et al, 2009).
In response, consensus-based recommendations for BSC delivery
were published in 2012 which sought to improve the internal and
external validity of BSC trials for patients with advanced cancer
(Zafar et al, 2012).
Using the recently published consensus-based framework for
the delivery of BSC in clinical trials, we aimed to determine how
well this framework reflects reporting standards for recently
Table 3. Clinical trial conformance to BSC statements and
CONSORT guidelines
Domain assessed Yes
Conformance to BSC consensus standards in clinical trials
Standardized BSC across sites if multisite 0%
BSC delivery standardized 6%
Clear description of BSC 33%
Symptom assessment at regular intervals 61%
Symptom assessment with valid tools 44%
Symptom assessment identical both arms 33%
Symptom management is evidence based 0%
Reported educating patients about symptom management 0%
Reported educating patients about goals of therapy 0%
Provided access to palliative specialists 0%
Provided access to support services 11%
Education about goals, importance of symptom assessment/
management
0%
Conformance to consort checklist for RCT’s
Eligibility criteria 100%
Documentation of settings 11%
Interventions described sufficiently 0%
Generalizable results (must have met all three of the above
CONSORT criteria)
0%



















Not published between 2002–12, inclusive = 224
Not a randomized controlled trial = 167
Non-human trial = 11
No BSC control arm =15
Did not include chemotherapy, radiation,
biologic agent, or any combination = 53
Duplicate study or secondary publication from
primary trial = 15
Non-English = 2
Non-advanced cancer = 8
Placebo controlled = 3
3 articles found by reviewing article citations
18 articles
evaluated
Figure 2. Literature review exclusion tree.
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published trials. Our current assessment of how well RCTs reflect
these published BSC guidelines demonstrates potential avenues to
improve the standardized delivery and documentation of suppor-
tive care in these trials. Most of the studies reported assessing
patients’ symptoms at regular intervals, but fewer reported using
validated tools or standardizing these assessments across both
arms. Furthermore, none of the articles discussed educating
patients about the importance of symptom management, nor did
they mention providing symptom management according to
evidence-based standards. This lack of facilitation to access BSC,
and poor standardization of symptom assessment and manage-
ment in BSC trials merits attention, as BSC trials should deliver
consistent, standardized supportive care according to published
guidelines and evidence-based practice.
Standardization of supportive and palliative care in BSC trials is
particularly important, as recent studies have found that patients
with advanced cancer who receive palliative care experience
improved quality of life, mood, and possibly even survival
(Bakitas et al, 2009; Temel et al, 2010; El-Jawahri et al, 2011;
Zimmermann et al, 2014). Access to palliative care should be
provided early in the course of illness for patients with advanced
cancer (Smith et al, 2012), especially those assigned to BSC
in a clinical trial. The American Society of Clinical Oncology
(Ferris et al, 2009) and the European Society of Medical Oncology
(Cherny et al, 2003) both recommend the appropriate provision of
supportive and palliative care services to patients with cancer. Our
review of the BSC literature found that none of the recent trials
document that patients had access to palliative care specialists.
Additionally, these trials rarely report that patients had access to
other support services, including nursing, social work, financial
and spiritual counseling. Given that studies continue to show the
benefits of providing optimal supportive care, BSC trials must aim
to deliver care that complies with these accepted standards.
When BSC trials do not deliver standardized supportive care,
researchers risk systematically over-estimating the net clinical
effect of the comparator arms. This threat to internal validity calls
into question the conclusions derived from the data. Notably, over
half of the studies we analyzed found an advantage for the
intervention arm compared with the BSC arm, but the use of
substandard control arms may have inflated the effect sizes of the
interventions. Furthermore, inconsistent reporting of the interven-
tions received by the BSC control arm generates irreproducible
data. Trial results that do not generalize to routine clinical practice
lack external validity. Thus, in order for BSC trials to prove
clinically meaningful results, researchers must provide consistent,
evidence-based, and standardized BSC to all trial participants.
We recognize that all of the studies reviewed were published
between 2002 and 2014. Thus, the study protocols were mostly
written and implemented prior to the publication of the BSC
Delphi recommendations. Hence, this current review serves as a
‘line in the sand’ documenting the current state and heralding an
opportunity for improvement. Monitoring uptake of the standar-
dized BSC framework over time will be illustrative, as perhaps the
impact of the consensus recommendations will reverberate more
with future BSC studies.
Proper trial design does not allow for poorly defined
interventions and variation between sites. Consequently, our
results show that studies complied with the selected CONSORT
guidelines better than they did with the BSC consensus guide-
lines. Previously, a literature review of oncology trial compliance
to the CONSORT checklist has shown that compliance improved
over time, with the most recently published studies showing
better reporting (Rodrigues et al, 2011). Although the included
articles in our current review were reported after the publication
of the BSC consensus statements, we did not specifically aim to
track compliance with those standards. Rather, we aimed to
determine how well those standards reflected contemporary
clinical trial design. Therefore, just as compliance to the
CONSORT checklist has improved over time, we hope com-
pliance to the published BSC standards will improve in future
BSC trials. Meanwhile, researchers, review boards, medical
editors, and their peer reviewers should ensure that BSC trials
adhere to accepted BSC standards.
In conclusion, inconsistent reporting of supportive care in BSC
trials persists. In light of the recently published BSC consensus
guidelines, our literature review highlights the need to improve the
standardized delivery and documentation of supportive care in
BSC trials. Patients with advanced cancer enrolled on clinical trials
expect care based on the best available evidence, but too often BSC
studies fail to standardize BSC delivery across trial sites, lack
evidence-based symptom management, and do not provide access
to palliative or supportive care services. These problems with trial
design threaten internal and external validity, resulting in biased
outcomes and potentially flawed conclusions. Researchers can
overcome these threats by integrating the published BSC standards
into their BSC RCTs, and improving their subsequent documenta-
tion of the components of their BSC control arm. Future efforts to
improve BSC trial design will need to determine the feasibility of
implementing the current BSC standards, and continue to adapt
subsequent recommendations according to the standard of care
and in concordance with the best available evidence.
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